Complete remission of nephrotic syndrome in secondary amyloidosis of familial Mediterranean fever following colchicine treatment
Ateş, artrit ve karın ağrısı atakları ile 18 yıldır ailevi Akdeniz ateşi hikayesi olan 25 yaşında Türk kadın hasta, 1999 yılında nefrotik sendrom kliniği ile hastanemize başvurdu. Renal ve intestinal mukozadan (rektum) yapılan biyopsilerde amiloid depolanması saptandı. Hastada homozigot M694V mutasyonu mevcut idi. Kolşisin tedavisi altında klinik belirtiler ve nefrotik düzeydeki proteinüri kayboldu. Literatürde benzer vakalar nadir olarak tarif edilmiştir. Bu hastada ailevi Akdeniz ateşin tanı ve tedavisinde 18 yıllık bir gecikme ve kolşisin tedavisi altında sekonder amiloidozise bağlı nefrotik sendromun kaybolarak iyi bir seyir göstermesi tartışıldı.
Ailevi Akdeniz ateşi ve sekonder amiloidosize bağlı nefrotik sendromun kolşisin tedavisi altında remisyonu
A 25-year-old woman of Turkish origin with an 18 year long history of familial Mediterranean fever (FMF) attacks characterized with fever, arthritis and abdominal pain developed symptoms of the nephrotic syndrome in 1999. The renal biopsy revealed small amounts of amyloid deposits. Intestinal mucosa (rectum) also showed amyloid infiltration. The patient was homozygous for M694V mutation. She has responded to colchicine with a resolution of clinical signs and nephrotic range proteinuria. Similar cases have been rarely described. In this case, an 18-year delayed diagnosis and treatment of FMF, reversible nephrotic stage of amyloidotic renal disease by colchicine and a favorable course were discussed .
___
- 1. Sohar E, Gafni J, Pras M et al. Familial Mediterranean fever: a survey of 470 cases and review of the literature. Am J Med 1967;43: 227-53
- 2. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-1885
- 3. Ravid M, Robson M, Kedar (Keizman) I: Prolonged colchicine treatment in four patients with amyloidosis. Ann Intern Med 1977;87: 568-570
- 4. Çakar N, Yalçınkaya F, Özkaya N et al. Familial Mediterranean fever (FMF)- associated amyloidosis in childhood Clinical features, course and outcome. Clin Exp Rheumatol 2001;19(5 Suppl 24) :S 63-7
- 5. Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992;116 (5):426.
- 6. Hojberg AS, Mertz H Nephrotic syndrome in familial Mediterranean fever-effect of colchicine therapy. Ugeskr Laeger 1995;10:157, 4035-4037
- 7. Rosenbaum M, Rosner I. Regression of amyloidosis with colchicine in familial Mediterranean fever in an Ashkenazi patient. Clin Exp Rheumatol 1995;13(1): 126.
- 8. Livneh A, Zemer D, Langevitz P et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994;37:1804-1811
- 9. Yalçınkaya F,Tekin M, Cakar N et al. Familial Mediterranean fever and systemic amyloidosis in treated Turkish patients. QJ Med 2000;93: 681-684
- 10. Yazıcı H, Özdoğan H Familial Mediterranean fever in Turkey In: Familial Mediterranean Fever (eds) Sohar E, Gafni J, Pras M. 1st International Conference of Familial Mediterranean Fever, September 7-11,1997, Freund publihing Hause Ltd London and Telaviv 66-71, 1997
- 11. Gershoni-Baruch R, Brik R, Shinawi M et al. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002:10(2): 145-149
- 12. Livneh A, Langevitz P, Shinar Y et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid Int Exp Clin Invest 1999;6: 1-6
- 13. Şimşek B, Islek I, Şimşek T et al. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant 2000;15: 281-282
- 14. Loweinstein J, Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. New Eng J Med 1970; 282: 128-132
- 15. Keven K, Nergisoğlu G, Ateş K et al. Remission of nephrotic syndrome after removal of localised Castleman’s disease. Am J Kidney Dis 2000; 35(6):1207-11